360° SearchNetwork Hot Spots Trends Time Series

Endologix Inc

Type: Company

Name: Endologix Inc

First reported May 20 2013 - Updated May 20 2013 - 1 reports

Shares of Endologix Under Pressure,...

Down 2.6% to $13.58, Endologix (NASDAQ:ELGX), is one of today's notable movers. The Dow is down 0.5% to 12,939 and the S&P is currently down 0.5% to 1,403.Endologix, Inc. develops, manufactures, sells, and markets minimally invasive treatments for vascular ... [Published Financial News Network online - May 20 2013]

Entities: Endologix Inc, Stocks, Moving Average, Aortic Aneurysm, Stent

First reported May 20 2013 - Updated May 20 2013 - 1 reports

Endologix Earnings In Retrospect: Down...

When Endologix (NASDAQ:ELGX) reported earnings 18 days ago on April 30th, 2013, analysts, on average, expected the company to report a loss of $0.06 on sales of $29.3 million. Endologix actually reported a loss of $0.07 per share on sales of $29.8 million, ... [Published Financial News Network online - May 20 2013]

Entities: Endologix Inc, Aortic Aneurysm, Stent, Stocks

First reported May 13 2013 - Updated May 13 2013 - 1 reports

Endologix reports lower Q1 net loss, provides outlook for 2013

Endologix, Inc., a medical device company, has reported that net loss for the first quarter ended March 31, 2013 was $9.33 million, or $0.15 loss per share, compared to a net loss of $16.70 million, or $0.29 loss per share, for the same quarter ended ... [Published Individual.com - May 13 2013]

Entities: Endologix Inc, Nellix Endovascular Inc, Kidney

First reported May 08 2013 - Updated May 08 2013 - 2 reports

Endologix to Participate in Three Upcoming Investor Conferences

CONTACT: COMPANY CONTACT:Endologix, Inc.John McDermott, CEOShelley Thunen, CFO(949) 595-7200www.endologix.comINVESTOR CONTACTS:The Ruth GroupNick Laudico (646) 536-7030Zack Kubow (646) 536-7 ... [Published Reuters - May 08 2013]

Entities: Endologix Inc, John McDermott

First reported May 04 2013 - Updated May 04 2013 - 1 reports

Endologix, Inc. (ELGX) - Product Pipeline Analysis, 2013 Update

SummaryEndologix, Inc. (Endologix) is a medical device company. It undertakes the development, manufacturing and selling of minimally invasive treatments for aortic diseases. The company lays focus on its patented technology for the treatment of Abdominal ... [Published Research and Markets - May 04 2013]

Entities: Endologix Inc, Pipeline, Aortic Aneurysm, Medical Devices, treatments

First reported May 02 2013 - Updated May 02 2013 - 2 reports

Potential Endologix (ELGX) Trade Has $11.60 Breakeven

Endologix Inc. (NASDAQ: ELGX) closed Wednesday's trading session at $14.00. In the past year, the stock has hit a 52-week low of $11.15 and 52-week high of $16.39. Endologix (ELGX) stock has been showing support around $13.29 and resistance in the $15.07 ... [Published Individual.com - May 02 2013]

Entities: Endologix Inc, Dividend Yield, Stock Prices

First reported May 02 2013 - Updated May 02 2013 - 1 reports

Endologix PT Lowered to $17.00 (ELGX)

Analysts at Lazard Capital Markets lowered their price target on shares of Endologix (NASDAQ: ELGX) Endologix (NASDAQ: ELGX) traded down 6.79% on Wednesday, hitting $14.00. Endologix has a 1-year low of $11.15 and a 1-year high of $16.39. The stock's ... [Published American Banking News - Stock Ratings - May 02 2013]

Entities: Endologix Inc, Abdominal Aortic Aneurysm, Earnings Per Share, Lazard Capital Markets

First reported May 01 2013 - Updated May 01 2013 - 1 reports

Endologix Reaffirms

Endologix Inc (NASDAQ: ELGX) said it continues to expect a 2013 GAAP loss of $0.17 to $0.14 per share on revenue of $126.0 million to $133.0 million. The current consensus estimate is a loss of $0.14 per share on revenue of $130.8 million for the year ... [Published Zecco - May 01 2013]

Entities: Endologix Inc

First reported Apr 30 2013 - Updated Apr 30 2013 - 1 reports

Endologix Inc Reiterates FY 2013 Guidance

Endologix Inc announced that based on the first quarter 2013 results and recent developments, it is reiterating fiscal 2013 financial guidance and anticipates revenue to be in the range of $126-$133 million and a GAAP loss in 2013 of $(0.14) to $(0.17) ... [Published Reuters - Apr 30 2013]

Entities: Endologix Inc, Nellix Endovascular Inc, B E S Ltd

First reported Apr 30 2013 - Updated Apr 30 2013 - 1 reports

Endologix (ELGX) Posts Quarterly Earnings Results, Misses Expectations By $0.09 EPS

Endologix (NASDAQ: ELGX) announced its earnings results on Tuesday. The company reported ($0.15) earnings per share for the quarter, missing the analysts' consensus estimate of ($0.06) by $0.09, Analyst Ratings Network.com reports. The company had revenue ... [Published American Banking News - Earnings - Apr 30 2013]

Entities: Endologix Inc, Abdominal Aortic Aneurysm, Earnings Per Share

First reported Apr 30 2013 - Updated Apr 30 2013 - 1 reports

Endologix (ELGX) Updates FY13 Earnings Guidance

Endologix (NASDAQ: ELGX) issued an update on its FY13 earnings guidance on Tuesday morning. The company provided EPS guidance of ($0.17)-(0.14) for the period, compared to the Thomson Reuters consensus EPS estimate of ($0.14), StocKRatingsNetwork.com ... [Published American Banking News - Apr 30 2013]

Entities: Endologix Inc, Earnings Per Share, Abdominal Aortic Aneurysm

First reported Apr 30 2013 - Updated Apr 30 2013 - 1 reports

Endologix Shares Climbing Higher, Up 1.8%

One of today's notable stocks on the rise is Endologix (NASDAQ:ELGX), up 1.8% to $14.90. The S&P is trading fractionally higher to 1,596 and the Dow is trading fractionally higher to 14,820.Endologix, Inc. develops, manufactures, sells, and markets minimally ... [Published Scottrade - Apr 30 2013]

Entities: Endologix Inc, Stocks, fractionation

Quotes

John McDermott, Endologix President and CEO, said, "We are very pleased with our sales growth in the US and international markets in the first quarter 2013, driven by continued adoption of the AFX Endovascular AAA System. In Europe, we began the limited market introduction of the Nellix EndoVascular Aneurysm Sealing System and have received very positive physician feedback on its ease-of-use and clinical outcomes from these first commercial procedures. In addition, we recently received FDA approval for our percutaneous EVAR (PEVAR) indication with AFX and have physician training courses scheduled to begin in May. After our first 120 procedures with the Ventana Fenestrated System, we have seen good overall safety results, but a higher than expected number of renal re-interventions. Before we continue enrolling patients in the IDE clinical study and begin the EU limited introduction, we plan to integrate our next generation covered renal stent and conduct additional testing and training to optimize future outcomes. We hope to begin enrolling patients in the study again and start the limited market introduction in Europe by the end of this year."

Endologix reports lower Q1 net loss, provides outlook for 2013 [Published Individual.com - May 13 2013]

"After seeing a number of first-quarter earnings come in below expectations, Sourcefire bucked the trend posting a solid quarter, which although slightly below the Street, was in-line with guidance" Lazard Capital analyst Joel Fishbein said in a note to clients

MARKET PULSE-Merck, Titan Pharma, Neutral Tandem, Synacor, Accelrys [Published CNBC - May 01 2013]

Mr. McDermott concluded, "Despite the temporary delay in the Ventana program, we are reiterating our guidance for the year based on the strong performance trends in our core business. We continue to believe Ventana represents a significant new innovation in the treatment of juxta and para-renal aortic aneurysms, with the potential to expand the addressable EVAR market. In addition, the limited market introduction of Nellix is going extremely well and we hope to begin enrolling patients in the U S IDE by the end of this year"

Endologix Reports 22% Revenue Growth for the First Quarter 2013 [Published Zecco - Apr 30 2013]

...By tracking the size and price of each montha'a "s short transactions, SQUEEZETRIGGER.COM provides institutions, traders, analysts, journalists and individual investors the exact price point where short sellers start losing money and a short squeeze can begin."

ELGX, PRAA, SIMG, FEIC, RGC, SKT Expected To Be Up After Next Earnings Releases [Published Individual.com - Apr 29 2013]

More Content

sort by: Date \| Relevance
Shares of Endologix Under Pressure,... [Published Financial News Network online - May 20 2013]
Endologix Earnings In Retrospect: Down... [Published Financial News Network online - May 20 2013]
Endologix reports lower Q1 net loss, provides o... [Published Individual.com - May 13 2013]
Polar Cap Gbl Healthcare Growth&IT - Half Yearl... [Published Morningstar UK - May 09 2013]
Endologix to Participate in Three Upcoming Inve... [Published Reuters - May 08 2013]
Endologix to Participate in Three Upcoming Inve... [Published GlobeNewswire: Acquisitions News - May 08 2013]
Endologix to Participate in Three Upcoming Inve... [Published Zecco - May 08 2013]
Endologix, Inc. (ELGX) - Product Pipeline Analy... [Published Research and Markets - May 04 2013]
Potential Endologix (ELGX) Trade Has $11.60 Bre... [Published Individual.com - May 02 2013]
Shares of Endologix Underperformed its Peers in... [Published Individual.com - May 02 2013]
Potential Endologix (ELGX) Trade Has $11.60 Bre... [Published MarketIntelligenceCenter.com - May 02 2013]
Endologix PT Lowered to $17.00 (ELGX) [Published American Banking News - Stock Ratings - May 02 2013]
Trading Lower on Heavy Volume are Shares of End... [Published Individual.com - May 01 2013]
MARKET PULSE-Merck, Titan Pharma, Neutral Tande... [Published CNBC - May 01 2013]
MARKET PULSE-Merck, Titan Pharma, Neutral Tande... [Published London South East - May 01 2013]
MARKET PULSE-Merck, Titan Pharma, Neutral Tande... [Published CNBC - May 01 2013]
MARKET PULSE-Merck, Chesapeake Energy, Masterca... [Published CNBC - May 01 2013]
Endologix Reaffirms [Published Zecco - May 01 2013]
Endologix Earnings: Here’s Why Investors are Am... [Published Wall St. Cheat Sheet - May 01 2013]
Endologix's CEO Discusses Q1 2013 Results - Ear... [Published Healthcare Sector and Stocks Analysis from Seek ... - May 01 2013]
Endologix Inc Reiterates FY 2013 Guidance [Published Reuters - Apr 30 2013]
Endologix (ELGX) Posts Quarterly Earnings Resul... [Published American Banking News - Earnings - Apr 30 2013]
Endologix (ELGX): Q1 EPS of -$0.07 misses by $0... [Published Seeking Alpha - Apr 30 2013]
Endologix (ELGX) Updates FY13 Earnings Guidance [Published American Banking News - Apr 30 2013]
Endologix Reports 22% Revenue Growth for the Fi... [Published GlobeNewswire: Acquisitions News - Apr 30 2013]
8-K - ENDOLOGIX INC /DE/ (0001013606) (Filer) [Published SEC Filings - Apr 30 2013]
Endologix Reports 22% Revenue Growth for the Fi... [Published Reuters - Apr 30 2013]
Endologix Reports 22% Revenue Growth for the Fi... [Published Zecco - Apr 30 2013]
Endologix Shares Climbing Higher, Up 1.8% [Published Scottrade - Apr 30 2013]
ELGX, PRAA, SIMG, FEIC, RGC, SKT Expected To Be... [Published Individual.com - Apr 29 2013]

Blogs

sort by: Date \| Relevance
Potential Endologix (ELGX) Trade Has $11.60 Bre... [Published MarketIntelligenceCenter.com - May 02 2013] Endologix Inc. (NASDAQ: ELGX) closed Wednesday's trading session at $14.00. In the past year, the stock has hit a 52-week low of $11.15 and 52-week high of $16.39. Endologix (ELGX) stock has been showing support around $13.29 and resistance in the $15.07 ...
Endologix Earnings: Here’s Why Investors are Am... [Published Wall St. Cheat Sheet - May 01 2013] Endologix Inc. ( NASDAQ:ELGX ) had a loss and missed Wall Street’s expectations, BUT beat the revenue expectation. The revenue beat is a positive sign to shareholders seeking high growth out of the company. Markets are at 5-year highs! Discover the ...
Endologix (ELGX) Could Fall Through $14.74 Supp... [Published MarketIntelligenceCenter.com - Apr 09 2013] Endologix Inc. (NASDAQ: ELGX) closed Monday's trading session at $15.41. In the past year, the stock has hit a 52-week low of $11.15 and 52-week high of $16.39. Endologix (ELGX) stock has been showing support around $14.74 and resistance in the $15.78 ...
Potential Endologix (ELGX) Trade Has 12.69% Dow... [Published MarketIntelligenceCenter.com - Apr 01 2013] Endologix Inc. (NASDAQ: ELGX) closed Thursday's trading session at $16.15. In the past year, the stock has hit a 52-week low of $11.15 and 52-week high of $16.39. Endologix (ELGX) stock has been showing support around $15.74 and resistance in the $16.48 ...
Potential Endologix (ELGX) Trade Targets 19.90%... [Published MarketIntelligenceCenter.com - Mar 22 2013] Endologix Inc. (NASDAQ: ELGX) closed Thursday's trading session at $15.73. In the past year, the stock has hit a 52-week low of $11.15 and 52-week high of $16.33. Endologix (ELGX) stock has been showing support around $15.41 and resistance in the $16.15 ...

Press Releases

sort by: Date \| Relevance
Endologix to Participate in Three Upcoming Inve... [Published GlobeNewswire: Acquisitions News - May 08 2013]
Endologix Reports 22% Revenue Growth for the Fi... [Published GlobeNewswire: Acquisitions News - Apr 30 2013]
Endologix Announces FDA Approval of First Percu... [Published GlobeNewswire: Acquisitions News - Apr 16 2013]
Research and Markets: Analysis of Endologix, Inc [Published Business Wire Professional Services News - Apr 16 2013]
Research and Markets: Analysis of Endologix, Inc [Published Business Wire Manufacturing News - Apr 16 2013]